UB#INBIORC2701A(54561.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
UB#INBIORC2701A
54561.HK
News
View More

Innovent receives fast track designation from FDA for IBI3003, a trispecific antibody for multiple myeloma. Jan. 26, 2026.

On January 26, 2026, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical firm based in San Francisco and Suzhou, China, specializes in the development, production, and distribution of top-tier medications. Their focus is on treating various conditions including oncologic, autoimmune, and cardiovascular diseases.

Unusual Whales·
HK
01801
0.00%
Unusual Whales·
HK
01801
0.00%

FDA Grants Fast Track Designation to Innovent's IBI3003 for Relapsed or Refractory Multiple Myeloma

Innovent Biologics Inc. has received Fast Track Designation from the FDA for its trispecific antibody IBI3003, aimed at treating relapsed or refractory multiple myeloma in patients with extensive prior therapy. This designation will expedite the development and review process for IBI3003, which is currently in Phase 1/2 clinical trials in China and Australia, with plans for trials in the U.S.

Reuters·
HK
01801
0.00%
Reuters·
HK
01801
0.00%

"Major Banks" Guosen Securities lists the top ten stocks for foreign capital inflows and outflows in Hong Kong stocks last quarter (Table)

Guotai Junan Securities released a report listing the top ten stocks for foreign capital inflows and outflows in Hong Kong stocks in the fourth quarter of last year. In terms of inflows, INNOVENT BIO ranked first with HKD 6.43 billion, followed by Xiexin Technology and SMIC, with HKD 5.31 billion and HKD 5.28 billion respectively. In terms of outflows, XIAOMI-W topped the list with HKD 50.41 billion, while ALI HEALTH and HSBC HOLDINGS had outflows of HKD 21.13 billion and HKD 16.23 billion respectively

AASTOCKS·
HK
00005
0.00%
HK
01801
0.00%
HK
01810
0.00%
AASTOCKS·
HK
00005
0.00%
HK
01801
0.00%
HK
01810
0.00%

Innovent Biologics: Rising Star in Biopharma

Innovent Biologics is emerging as a leader in China's biopharma sector, shifting from generics to innovative biopharmaceuticals. With revenues projected to reach USD 126.6 billion by 2030, the company has launched 18 products and has a robust pipeline. In Q3 2025, it reported a 40% year-on-year revenue increase, driven by successful oncology drugs. Analysts are optimistic, with a consensus target price indicating a potential 25.5% upside. However, challenges such as regulatory pressures and competition remain. Innovent's focus on innovation positions it for significant growth in the global biopharma landscape.

marketscreener·
HK
01801
0.00%
marketscreener·
HK
01801
0.00%

Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial

Innovent Biologics Inc. and Ollin Biosciences reported positive Phase 1b results for IBI324 in a clinical trial for diabetic macular edema and wet age-related macular degeneration. The study showed IBI324's superior outcomes compared to faricimab, with plans to advance to global Phase 3 studies. Full results will be presented at a symposium in February 2026.

Reuters·
HK
01801
0.00%
Reuters·
HK
01801
0.00%
Posts
View More
© 2026 Longbridge｜Disclaimer